| BT7480, a novel fully synthetic Bicycle tumor-targeted immune cell agonist™(Bicycle TICA™) induces tumor localized CD137 agonism K Hurov, J Lahdenranta, P Upadhyaya, E Haines, H Cohen, E Repash, ... Journal for immunotherapy of cancer 9 (11), 2021 | 27 | 2021 |
| 706 BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment P Upadhyaya, K Hurov, J Kublin, J Ma, E Repash, M Kleyman, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 2 | 2020 |
| Nectin-4-dependent immune cell stimulation and anti-tumor efficacy by BT7480, a Nectin-4/CD137 Bicycle® tumor-targeted immune cell agonist (TICA™) K Hurov, J Lahdenranta, P Upadhyaya, D Kanakia, E Repash, F You, ... Cancer Res 81 (13_Supplement), 1728-1728, 2021 | 1 | 2021 |
| Abstract A65: Development of a CD137 receptor occupancy assay to support the Phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell agonist®(Bicycle TICA™) H Cohen, C Bray, D Kanakia, J Lahdenranta, P Upadhyaya, K Hurov, ... Cancer Immunology Research 10 (12_Supplement), A65-A65, 2022 | | 2022 |
| Development of a CD137 receptor occupancy assay to support the phase I/II study of BT7480, a Bicycle® tumor-targeted immune cell agonist (Bicycle TICA™) H Cohen, D Kanakia, J Lahdenranta, P Upadhyaya, K Hurov, ... Cancer Research 82 (12), 2022 | | 2022 |
| Development of CD137 (4-1BB) receptor occupancy assay using fluorescently labeled Bicycles® D Kanakia, P Upadhyaya, J Lahdenranta, E Repash, E Haines, ... Cancer Immunology Research 9 (2), 2021 | | 2021 |
